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Abstract: 
Recent clinical trials have movedI-131 MIBG therapy into frontline management of 
high-risk neuroblastoma. With this expansion, it is reasonable to anticipate the need 
for intensive care level resuscitations. Radiation exposureremains the greatest risk to 
healthcare professionals managing these patients.We combined shock simulation 
scenario data with actualradiation dosimetry data to create a care model allowing for 
aggressive, prolonged in situ resuscitation of a critically ill pediatric patient after I-131 
MIBG administration. This model will maintain a critical care provider’s radiation level 




Radioactive MIBG (metaiodobenzylguanidine) therapy is a targeted radiotherapy 
agent historically used for the treatment of relapsed or refractory neuroblastoma.  
Based upon promising response rates, recent clinical trials are moving MIBG therapy 
into front-line management of high-risk neuroblastoma.1-8Radiation exposure from 
iodine-131 (I-131) remains the greatest risk to healthcare professionals managing 
these patients.9-11 In the United States, occupational radiation dose limits are found 
in Title 10, Part 20 of the Code of Federal Regulations (10 CFR 20), or in equivalent 
Agreement State regulations. The annual adult occupational dose limitsare 50mSv 
(5,000 mrem), and 5 mSv (500 mrem) for the embryo/fetus of a declared pregnant 
woman(during the entire pregnancy).11,12 
 
Due to Federal guidelines governing the release of individuals containing radioactive 
material (10 CFR 35.75),13 patients receiving I-131 MIBG treatment are typically 
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131.In the event of acute, critical decline, it is undesirable for these patients to travel 
to diagnostic imaging or surgical suite facilities, or to have radioactive diagnostic 
samples sent to a clinical laboratory. During the infusion and in the days that follow, 
trainedpediatric intensive care (PICU) and oncology team members are on-call to 
respond to emergencies including, but not limited to, sedation complications, 
anaphylaxis, septic shock, acute respiratory failure, cardiovascular instability 
(hypertensive crises, arrhythmias)and acute neurologic deterioration. 
 
Radiation exposure tohealthcare professionals for routine care of patients receiving 
I-131 MIBG treatment are historically very low (<0.45 mSv = 45 mremper 
treatment).14-16 Unfortunately, these data do not reflect a potentially protracted time 
period at the bedside that would be required to adequately resuscitate a pediatric 
patient after severe, acute deterioration. Because multiple MIBG therapy patients are 
managed at Michigan Medicine annually, as part of our clinical practice guideline, we 
have established a radiation exposure goal of 5 mSv (500 mrem), or 10% of the 
annual occupational dose limit per healthcare professional per patient managed. Our 
goal was to create a care model that would allow for aggressive, in situ resuscitation 
of a critically ill pediatric patient after I-131 MIBG administration, while controlling 




A failure mode effects analysisidentified staffing needs as our greatest barrier in 
resuscitating a patient with acute, severe shock immediately after MIBG infusion in 




This article is protected by copyright. All rights reserved. 
 
pediatric patient during and after MIBG infusion with data from a shock resuscitation 
simulation to generate a proposed staffing model. 
 
Case Study: Concurrent with an existing MIBG treatment protocol approved by the 
Institutional Review Board, we placed fiveradiation dosimeters (Landauer OSL) in 
selected locations of the isolation room(Figure 1).An 11 yo female with high risk 
neuroblastoma received 811 mCi (15.1 mCi/kg) of I-131 MIBG.Dosimetersrecorded 
exposure over selected time intervals for the first 96 hours after the infusion started.  
 
Shock scenario simulation: We also completed a paper simulation of a patient 
experiencing an acute shock-type event after the start of MIBG infusion and requiring 4 days 
of intensive care managementin situ. The scenario chosen was cardiac arrest, requiring full 
resuscitative efforts, including placement of monitors, rapid sequence intubation, mechanical 
ventilation and suctioning, peripheral, central venous and arterial vascular access completed 
in series, initiation and titration of vasoactive infusions, administration of sedation, analgesia, 
antibiotics and other medications, and emergent diagnostic testing. Emergent diagnostic 
testing for the deteriorated MIBG patient was limited to point-of-care blood testing and chest 
and abdominal radiographs.  
 
The shock simulation scenario data were merged with dosimetry datato estimate 
radiation doses for each team member, accrued across all time phases for the first 
4days after MIBG administration. The scenario accounts for the dynamic movement 
of each team member amongfive different positionsin the isolation room (Table1, 
Figure 1)and radiation dose rate reduction from the physical decay15 of Iodine-131 
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shifts, we determined thestaffing modelrequired to effect this same care in a real-life 




The highest dose rate is in position 2,at bedside and in front of the lead shield. Estimates 
indicate that a team member can remain in position 2 for the first 5 hours after infusion, the 
time of greatest radiation exposure, before reaching 5mSv (500 mrem). The next highest 
dose rate is in position 1(head of the bed), although the dose rate was often less than 25% 
of the dose rate in position 2. Any position behind a lead shield results in substantially less 
exposure(Table1, Figure 1). 
 
The simulation resulted in time-spent estimates of 288 minutes for PICU nurse, 155 minutes 
for PICU physician, 146 minutes for oncology nurse, 58 minutes for oncology physician, and 
76 minutes for PICU Respiratory Therapist (RT).  
 
Taken together, these data determined our staffing model(Supplemental Table): 
 
a) PICU physician: Two pediatric intensivists will be necessary, each prepared to 
work 12-hour shifts for the first 96 hours afterthe start of MIBG infusion. A 
third intensivist should be available in the event that one of the two primary 
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b) PICU nurse: For the first 24 hours, six PICUnurses will be needed, each 
working 8-hour shifts and rotating in 4-hour intervals between positions 2 and 
3. After the first 24 hours, PICU nurses may work a 12-hour shift in all 
positions. 
 
c) Respiratory therapist: For all time periods, one RT will be needed and may 





While maximal medical and surgical intensive care may not be an option for patients 
receiving MIBG therapy due to radiation safety concerns, this case study describes how 
critical care therapiesmaybe safely applied in situ for the first 4 days after the start of the 
infusion. Our data indicate that a team member spending all time at the location of highest 
radiation dose rate (at bedside and in front of the shield)would not exceed 10% of the annual 
occupational dose limit, unless remaining in that position for more than 5 hours. The goal of 
5mSv (500mrem)per patientallows team members to safely manage multiple patients 
annually, even in the unlikely event of multiple deteriorations. 
 
As these data reflect one patient and one simulation, our proposed model recommendsuse 
of real-time dosimeters for quick, on-demand monitoring, worn by each team member, with 
accumulated doses assessed after the first 4 hours and at 24-hour intervals to assist in 
refining the need for staffing rotation. When possible, we recommend only one physician, 
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door or behind a lead shield. Finally, should any team member exceed 5 mSv (500 
mrem,)we recommend they rotate out of the isolation room into the anteroom (position 5) for 
all remaining time.   
 
As MIBG treatment trials expand enrollment to include younger children and infants, 
as well as intravenous or multi-drug sedatives to ensure patient tolerance of the 
treatment, it is reasonable to anticipate the need for intensive care level 
resuscitations.17Our model endorsesthat pediatric critical care level resuscitation and 
management can be achieved in situwhile adequately controlling occupational 
radiation exposures. 
Ongoing work is necessary to replicate our findings,perhaps with shorter monitoring 
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FIGURE 1 Schematic of actual patient room noting each of 5 radiation dosimeter 
locations.Dark lines represent portable lead shields. Double lines represent walls. Rectangle 
represents patient bed. Hexagons represent locations of dosimeters: 1 - at head of bed, 2 - 
at side of bed but in front of lead shield, 3 - at side of bed but behind lead shield, 4 – on wall 
within room, 5 – at doorway entrance to MIBG room 
TABLE 1 Mean radiation doses (mrem/hr, 1mSv=100mrem)recorded over selected time 
intervals for the first 96 hours after I-131 MIBG infusion start at each of 5 patient room 





(mrem/hr) 0-4 hrs 4-16*hrs 16-24 hrs 24-48 hrs 48-75hrs 75-96 hrs 
1 - Head 
of Bed 56 23 27 15 14 3 
2 - Side of 
bed – in 
front of 
shield 103 89 96 59 34 21 
3 - Side of 
bed – 
behind 
shield 5 2 1 <1 <1 <1 
4 - Side 
wall of 
patient 




room 5 <1 <1 <1 <1 <1 
 
